# China Thrombus Treatment Market > China Thrombus Treatment Market Research Report By Type (Atrial Thrombus, Venous Thrombus) and By Treatment (Medical Therapy, Surgery, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.57% - **2024:** $ 2,416.2 Million - **2025:** $ 2,574.94 Million - **2035:** $ 4,866.42 Million - **Key Players:** Bayer AG (DE), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Roche Holding AG (CH), Sanofi S.A. (FR), Abbott Laboratories (US), Medtronic plc (IE), Cardinal Health, Inc. (US) **Report ID:** MRFR/HC/51844-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-thrombus-treatment-market-53605 --- ## Market Summary ## **China Thrombus Treatment Market Overview** As per MRFR analysis, the China Thrombus Treatment Market Size was estimated at 2.37 (USD Billion) in 2023.The China Thrombus Treatment Market is expected to grow from 2.42(USD Billion) in 2024 to 5.02 (USD Billion) by 2035. The China Thrombus Treatment Market CAGR (growth rate) is expected to be around 6.881% during the forecast period (2025 - 2035). **Key China Thrombus Treatment Market Trends Highlighted** The rising incidence of thromboembolic illnesses, the aging of the population, and the development of medical technology are all driving major trends in the China thrombus treatment market. In an effort to increase access to and treatment choices for thrombus-related diseases, the Chinese government is aggressively pushing healthcare reforms. In order to improve patient outcomes, this change in emphasis is pushing medical professionals to embrace novel treatments and make sure they are generally accessible. Effective thrombus therapies are becoming more and more necessary in China because to the rising prevalence of lifestyle disorders like diabetes and hypertension, which is driving market expansion. Local pharmaceutical businesses are investing more in research and development, which is boosting opportunities in the China thrombus treatment market. These businesses are investigating cutting-edge treatments that can improve treatment effectiveness, such as anticoagulants and minimally invasive procedures. Additionally, thrombus treatment is increasingly moving toward personalized medicine, which enables customized medicines to match the needs of individual patients. A special chance to enhance patient management and healthcare delivery in thrombus treatment is also presented by the incorporation of digital health technology, such as telemedicine and remote monitoring. There has been a recent tendency in China toward raising general public knowledge of thrombus-related disorders. This has raised the need for thrombus treatment options and encouraged more proactive health-seeking habits. Furthermore, partnerships between the private sector and public health organizations are encouraging information exchange and creative treatment strategies. The market for thrombus treatments is expected to develop with encouraging growth potential as China keeps improving its healthcare capabilities. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **China Thrombus Treatment Market Drivers** **Increasing Prevalence of Cardiovascular Diseases** The China [Thrombus Treatment Market](../../../reports/thrombus-treatment-market-11453) is experiencing significant growth driven by the rising prevalence of cardiovascular diseases. According to the National Health Commission of China, cardiovascular diseases account for approximately 40% of all deaths in the country. In the last decade, the incidence of cardiovascular issues has seen a continuous upward trend due to aging population and lifestyle changes, with nearly 290 million individuals currently affected. Major organizations such as the Chinese Society of Cardiology are actively promoting awareness and research into treatment options. This growing population of patients creates a demand for effective thrombus treatments, further propelling the industry forward. **Advancements in Medical Technology and Treatments** Technological innovations in thrombus treatment and related medical devices are significantly driving the China Thrombus Treatment Market. The Chinese government has been investing heavily in Research and Development (R&D), with a 10% annual increase in budget allocation towards healthcare technologies, resulting in better and more effective treatment options. Companies like Shanghai MicroPort Medical (Group) Co., Ltd. are leading the way in developing minimally invasive solutions that effectively manage thrombus-related conditions. This focus on innovation is improving patient outcomes while also attracting more investment in the sector. **Government Initiatives for Healthcare Access** The Chinese government has initiated numerous policies aimed at improving healthcare access, which is beneficial for the China Thrombus Treatment Market. The Healthy China 2030 initiative emphasizes the importance of chronic disease management and prevention strategies, targeting better healthcare delivery systems. With investments exceeding 160 billion USD in health infrastructure over the next decade, hospitals and clinics are better equipped to provide thrombus treatment. This governmental commitment to enhancing healthcare accessibility ensures a growing patient base that requires advanced thrombus treatments and technologies. **Rising Awareness and Educational Campaigns** Growing awareness about thrombus and related health complications contributes significantly to the China Thrombus Treatment Market. The Chinese government and various health organizations are spearheading educational campaigns to inform the public about the risks associated with thrombus-related diseases. The World Health Organization reported a 25% increase in public awareness regarding stroke prevention in recent years, linked to these campaigns. These efforts help in early diagnosis and treatment initiation, thereby propelling demand for thrombus treatment solutions. **China Thrombus Treatment Market Segment Insights** **Thrombus Treatment Market Type Insights** The China Thrombus Treatment Market is witnessing significant growth, primarily driven by the increasing prevalence of thromboembolic diseases and a rising geriatric population. Within this market, the Type segmentation reveals a critical distinction between Atrial Thrombus and Venous Thrombus, each playing a pivotal role in the therapy strategies adopted in clinical settings. Atrial Thrombus, which is primarily associated with conditions such as atrial fibrillation, necessitates prompt intervention and offers an array of treatment options that are crucial for preventing strokes. The importance of timely treatment in this segment cannot be understated; as delays can lead to severe complications and increased healthcare costs, this segment remains a vital focus area for both Research and Development and healthcare policies aimed at improving patient outcomes. In contrast, Venous Thrombus is largely related to conditions like deep vein thrombosis and pulmonary embolism, with rising incidences attributed to sedentary lifestyles and increasing rates of obesity among the Chinese population, triggering the adoption of advanced treatment protocols. The treatment mechanisms here often involve anticoagulants and thrombolytics, making it crucial for market players to focus on innovations that enhance early diagnosis and therapy efficacy. The growing awareness surrounding these conditions in China, accompanied by increased healthcare spending, underlines the significant potential for advancements in both treatment protocols and outcomes in the Venous Thrombus segment. Overall, the Type segmentation in the China Thrombus Treatment Market presents diverse opportunities for growth driven by changing demographics and advancements in medical technology. Understanding the unique characteristics and challenges associated with Atrial and Venous Thrombus is essential for developing targeted therapies. As healthcare providers increasingly emphasize personalized medicine, the need for tailored treatment solutions within these categories is expected to underline major developments in the industry. The push for improving healthcare access and affordability in China further complements these trends, creating a dynamic landscape for stakeholders in the thrombus treatment space. Addressing the complexities and distinct requirements of each segment holds the key to enhancing patient care and achieving better clinical outcomes, thereby establishing a robust foundation for market growth. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Thrombus Treatment Market Treatment Insights** The China Thrombus Treatment Market focuses on key advances in the Treatment segment, which is essential for managing thrombosis effectively. Medical Therapy is vital as it often serves as the first line of defense against thrombus formation, utilizing medications to dissolve clots and prevent further complications. Surgery, while less common, is crucial for cases where thrombus is extensive or life-threatening, as it can provide immediate relief and restore proper blood flow. Other treatment methods encompass various innovative therapies and approaches that are emerging in the market, reflecting the industry's commitment to providing diverse options for patient care. With the rise in cardiovascular disorders in China, attributed to lifestyle changes and an aging population, the Treatment segment is experiencing significant attention and investment. The overall growth of the China Thrombus Treatment Market is driven by factors such as increased awareness of thromboembolic conditions, ongoing Research and Development, and advancements in surgical techniques and pharmacological innovations, ensuring that the market is poised for considerable expansion in the years ahead. **China Thrombus Treatment Market Key Players and Competitive Insights** The China Thrombus Treatment Market has shown significant growth over the past few years, driven by an increase in cardiovascular diseases and the growing aging population. The competitive landscape of this market is characterized by a blend of established pharmaceutical companies and emerging biotech firms that are actively working to enhance treatment options for thrombus-related health issues. These companies are leveraging advanced technologies and innovative research methodologies to develop new therapeutic agents while navigating the unique regulatory environments and market dynamics in China. The need for effective therapies and the rise of personalized medicine have further intensified the competitive environment, as firms compete to establish their presence and secure market share in this rapidly evolving sector. Bristol-Myers Squibb has established a solid foothold in the China Thrombus Treatment Market, highlighting its commitment to addressing thrombotic conditions through a range of innovative therapies. The company benefits from its strong research and development capabilities, allowing it to maintain a pipeline of cutting-edge products aimed at treating various thrombus-related conditions. Bristol-Myers Squibb's reputation for high-quality medications and its strategic partnerships with local entities strengthen its market presence, facilitating better distribution and access to its therapies. The company is recognized for its focus on expanding treatment options for patients with cardiovascular diseases in China, which aligns well with the nation's healthcare goals. Abbott Laboratories plays a significant role in the China Thrombus Treatment Market with an emphasis on innovative medical devices and pharmaceuticals. The company's product portfolio includes a variety of solutions such as catheter-based interventions for thrombus extraction and advanced diagnostic tools for early detection. Abbott’s strong presence in China is bolstered by its ongoing efforts in research and development to introduce novel therapeutic solutions tailored to local healthcare needs. The company has been active in forming strategic alliances and mergers that enhance its capabilities and strengthen its market position, allowing it to deliver a comprehensive suite of products. Abbott's dedication to improving patient outcomes through its state-of-the-art technologies and robust healthcare network has positioned it as a leader in the thrombus treatment landscape within the region. **Key Companies in the China Thrombus Treatment Market Include:** - Bristol-Myers Squibb - Abbott Laboratories - Amgen - Stryker Corporation - Roche - St. Jude Medical - Johnson & Johnson - AngioDynamics - Medtronic - Boehringer Ingelheim - AstraZeneca - Terumo Corporation - Sanofi - Cardinal Health - Baxter International **China Thrombus Treatment****Market****Developments** The China Thrombus Treatment Market has recently witnessed significant developments, particularly with advances in medical technology and a rise in thrombotic disorders. Companies such as Bristol-Myers Squibb, Abbott Laboratories, and Amgen continue to innovate in drug formulations and delivery systems, enhancing patient outcomes. In September 2023, Amgen announced an expansion of its cardiovascular portfolio within China, addressing the increasing prevalence of thrombus-related conditions. Additionally, Stryker Corporation launched a new thrombectomy device in August 2023, aimed at improving procedural efficiency in hospitals across the country. The past few years have seen a growing market valuation, with investors focusing on companies like Roche and Johnson and Johnson, who are expanding their R&D capabilities in China. Notably, in March 2021, Boehringer Ingelheim introduced a novel anticoagulant therapy that has gained traction domestically. The market is further bolstered by the government's push for advanced healthcare solutions, aiming to reduce the burden of cardiovascular diseases within the nation. As such, the landscape for thrombus treatment continues to evolve, driven by both innovation and regulatory support in China. **China Thrombus Treatment Market Segmentation Insights** **Thrombus Treatment Market Type Outlook** - Atrial Thrombus - Venous Thrombus **Thrombus Treatment Market Treatment Outlook** - Medical Therapy - Surgery - Others ## Market Drivers ### Growing Aging Population China's demographic shift towards an aging population is a critical driver for the thrombus treatment market. As individuals age, the risk of thrombus formation increases, leading to a higher demand for effective treatment options. Projections suggest that by 2030, over 300 million people in China will be aged 60 and above, creating a substantial market for thrombus treatments. This demographic trend necessitates the development of specialized therapies tailored to the needs of older patients. Healthcare providers are likely to focus on creating comprehensive treatment plans that address the unique challenges faced by this population, thereby potentially expanding the thrombus treatment market. The intersection of aging and healthcare innovation may lead to new opportunities for growth in this sector. ### Increased Awareness and Education There is a growing awareness of thrombus-related health issues among the Chinese population, which is positively influencing the thrombus treatment market. Educational campaigns by healthcare organizations and government bodies are helping to inform the public about the risks associated with thrombus formation and the importance of timely treatment. This heightened awareness is likely to lead to increased patient engagement and proactive healthcare-seeking behavior. As individuals become more informed about their health, they may be more inclined to seek out thrombus treatment options, thereby driving market demand. Additionally, healthcare professionals are receiving enhanced training on thrombus management, which may improve treatment outcomes and further stimulate growth in the thrombus treatment market. ### Advancements in Medical Technology Technological innovations are playing a pivotal role in shaping the thrombus treatment market. The introduction of minimally invasive procedures and advanced imaging techniques has revolutionized the way thrombus-related conditions are diagnosed and treated. For instance, the use of catheter-based interventions has shown to reduce recovery times and improve patient outcomes. Additionally, the development of novel anticoagulants and thrombolytics is expanding treatment options available to healthcare professionals. As these technologies become more widely adopted, they are likely to enhance the efficacy of thrombus treatments, thereby attracting more patients and healthcare providers to the market. The integration of artificial intelligence in treatment planning may further optimize patient care, indicating a promising future for the thrombus treatment market. ### Government Initiatives and Funding The Chinese government is actively promoting initiatives aimed at improving cardiovascular health, which directly impacts the thrombus treatment market. Increased funding for research and development in this field is evident, with the government allocating substantial resources to healthcare innovation. This financial support is likely to facilitate the development of new treatment modalities and improve existing therapies. Furthermore, public health campaigns aimed at raising awareness about thrombus-related conditions are expected to encourage early diagnosis and treatment, potentially increasing the patient base. As a result, the thrombus treatment market may witness significant growth driven by these government-led initiatives, which aim to enhance overall healthcare outcomes in the country. ### Rising Incidence of Cardiovascular Diseases The thrombus treatment market in China is experiencing growth due to the increasing prevalence of cardiovascular diseases. Reports indicate that cardiovascular diseases account for approximately 40% of all deaths in the country. This alarming statistic highlights the urgent need for effective thrombus treatments. As the population ages and lifestyle-related risk factors such as obesity and diabetes become more common, the demand for thrombus treatment options is likely to rise. Healthcare providers are focusing on innovative therapies to address this growing health crisis, which is expected to drive market expansion. Furthermore, the Chinese government is investing in healthcare infrastructure, which may enhance access to thrombus treatment services, thereby potentially increasing patient outcomes and market growth. ## Future Outlook The [Thrombus Treatment Market](https://www.marketresearchfuture.com/reports/thrombus-treatment-market-11453) in China is projected to grow at a 6.57% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of thrombotic disorders, and enhanced healthcare infrastructure. **New opportunities:** - Development of AI-driven diagnostic tools for early thrombus detection. - Expansion of telehealth services for remote thrombus management. - Investment in biodegradable stents for improved patient outcomes. By 2035, the thrombus treatment market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Atrial Thrombus (Largest) vs. Venous Thrombus (Fastest-Growing) The market for thrombus treatment in China is primarily dominated by Atrial Thrombus, which holds a significant share in the overall segment. This type of thrombus is associated with atrial fibrillation and other cardiovascular conditions, leading to higher treatment demand. Venous Thrombus, while smaller in market share, is gaining traction due to increasing awareness and advancements in treatment modalities. Growth trends indicate a robust increase in demand for both Atrial and Venous Thrombus treatments. Factors such as an aging population, rising prevalence of cardiovascular diseases, and enhanced healthcare infrastructure contribute to this growth. Venous Thrombus is particularly seeing fast development due to innovative treatment options and growing patient awareness about thrombosis-related conditions. Atrial Thrombus (Dominant) vs. Venous Thrombus (Emerging) Atrial Thrombus is recognized as the dominant force in the thrombus treatment segment, driven by its strong correlation with prevalent heart conditions. It typically requires more complex management strategies and has benefited from technological advancements in medical devices and pharmacological treatments. On the other hand, Venous Thrombus is emerging as a significant player, bolstered by recent innovations and a better understanding of patient needs. The treatments for Venous Thrombus are becoming more sophisticated, with increased focus on preventing complications, which is drawing more attention from healthcare providers and patients alike. ### By Treatment: Medical Therapy (Largest) vs. Surgery (Fastest-Growing) In the China thrombus treatment market, Medical Therapy holds the largest share among the treatment segments, demonstrating the preference for non-invasive approaches to thrombus management. Surgery, while currently smaller in market share, is emerging as a critical option due to advancements in surgical techniques and technologies that enhance patient outcomes. Other treatments, while present, contribute minimally to the overall landscape. The market is witnessing robust growth driven by increasing awareness of thrombus-related conditions and the rising demand for effective treatment solutions. Medical Therapy continues to be favored due to its accessibility and lower risk profile, while Surgery is gaining traction as the fastest-growing segment. This shift is propelled by an aging population and the need for more immediate interventions, enhancing the importance of surgical options in the market. Medical Therapy (Dominant) vs. Surgery (Emerging) Medical Therapy is characterized by its non-invasive nature and is the dominant choice for many patients in the thrombus treatment landscape, as it offers effective management without the complications associated with surgical procedures. This segment is primarily driven by oral anticoagulants and novel therapies that have proven successful in reducing thrombus formation. On the other hand, Surgery is emerging as a vital segment, offering essential solutions for cases where medical therapy is insufficient. It is distinguished by innovative surgical methods that considerably reduce recovery times and improve outcomes, catering to patients with severe thrombotic conditions. Together, these segments illustrate the dynamic treatment options available to address thromboembolic disorders. ## Competitive Benchmarking The thrombus treatment market in China is characterized by a dynamic competitive landscape, driven by increasing incidences of thromboembolic disorders and a growing emphasis on advanced therapeutic solutions. Key players such as Bayer AG (DE), Bristol-Myers Squibb Company (US), and Johnson & Johnson (US) are strategically positioned to leverage innovation and regional expansion. Bayer AG (DE) focuses on enhancing its portfolio through research and development, while Bristol-Myers Squibb Company (US) emphasizes strategic partnerships to bolster its market presence. Johnson & Johnson (US) is actively pursuing digital transformation initiatives to improve patient outcomes, collectively shaping a competitive environment that prioritizes innovation and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of treatment options, although it also intensifies competition among established and emerging firms. In October Bayer AG (DE) announced a collaboration with a leading Chinese biotechnology firm to develop a novel thrombolytic agent. This strategic move is likely to enhance Bayer's research capabilities and expedite the introduction of innovative therapies tailored to the Chinese market. Such collaborations may significantly impact Bayer's competitive positioning by aligning its offerings with local healthcare needs. In September Bristol-Myers Squibb Company (US) launched a new digital platform aimed at improving patient engagement and adherence to thrombus treatment regimens. This initiative underscores the company's commitment to integrating technology into its therapeutic strategies, potentially leading to better patient outcomes and increased market share. The focus on digital solutions may also serve to differentiate Bristol-Myers Squibb in a crowded marketplace. In August Johnson & Johnson (US) expanded its product line by introducing a new catheter-based thrombectomy device designed for minimally invasive procedures. This innovation reflects the company's strategy to enhance its surgical offerings and cater to the growing demand for less invasive treatment options. By investing in advanced medical technologies, Johnson & Johnson is likely to strengthen its competitive edge in the thrombus treatment sector. As of November current trends in the thrombus treatment market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, positioning companies to better meet the complex needs of patients and healthcare providers. ## Recent News & Developments The China Thrombus Treatment Market has recently witnessed significant developments, particularly with advances in medical technology and a rise in thrombotic disorders. Companies such as Bristol-Myers Squibb, Abbott Laboratories, and Amgen continue to innovate in drug formulations and delivery systems, enhancing patient outcomes. In September 2023, Amgen announced an expansion of its cardiovascular portfolio within China, addressing the increasing prevalence of thrombus-related conditions. Additionally, Stryker Corporation launched a new thrombectomy device in August 2023, aimed at improving procedural efficiency in hospitals across the country. The past few years have seen a growing market valuation, with investors focusing on companies like Roche and Johnson and Johnson, who are expanding their R&D capabilities in China. Notably, in March 2021, Boehringer Ingelheim introduced a novel anticoagulant therapy that has gained traction domestically. The market is further bolstered by the government's push for advanced healthcare solutions, aiming to reduce the burden of cardiovascular diseases within the nation. As such, the landscape for thrombus treatment continues to evolve, driven by both innovation and regulatory support in China. ## Report Scope | MARKET SIZE 2024 | 2416.2(USD Million) | | --- | --- | | MARKET SIZE 2025 | 2574.94(USD Million) | | MARKET SIZE 2035 | 4866.42(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.57% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Bayer AG (DE), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Roche Holding AG (CH), Sanofi S.A. (FR), Abbott Laboratories (US), Medtronic plc (IE), Cardinal Health, Inc. (US) | | Segments Covered | Type, Treatment | | Key Market Opportunities | Advancements in minimally invasive techniques enhance patient outcomes in the thrombus treatment market. | | Key Market Dynamics | Rising demand for innovative thrombus treatment solutions driven by regulatory changes and competitive advancements in China. | | Countries Covered | China | ## Frequently Asked Questions **Q: What was the overall market valuation of the thrombus treatment market in 2024?** A: The overall market valuation was 2416.2 $ Million in 2024. **Q: What is the projected market valuation for the thrombus treatment market by 2035?** A: The projected valuation for 2035 is 4866.42 $ Million. **Q: What is the expected CAGR for the thrombus treatment market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 6.57%. **Q: Which segment had the highest valuation in 2024 within the thrombus treatment market?** A: The Venous Thrombus segment had the highest valuation at 1416.2 $ Million in 2024. **Q: What are the key treatment types in the thrombus treatment market?** A: The key treatment types include Medical Therapy, Surgery, and Others. **Q: What was the valuation of the Atrial Thrombus segment in 2024?** A: The Atrial Thrombus segment was valued at 1000.0 $ Million in 2024. **Q: How much is the Surgery segment projected to grow by 2035?** A: The Surgery segment is projected to grow to 1600.0 $ Million by 2035. **Q: Which companies are considered key players in the thrombus treatment market?** A: Key players include Bayer AG, Bristol-Myers Squibb Company, Johnson & Johnson, and Roche Holding AG. **Q: What was the valuation of the Others treatment segment in 2024?** A: The Others treatment segment was valued at 616.2 $ Million in 2024. **Q: What is the projected growth for the Venous Thrombus segment by 2035?** A: The Venous Thrombus segment is projected to reach 2866.42 $ Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-thrombus-treatment-market-53605*